⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CDTX News
Cidara Therapeutics, Inc.
Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025
globenewswire.com
CDTX
Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025
globenewswire.com
CDTX
Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention
globenewswire.com
CDTX
Cidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative Therapeutic
globenewswire.com
CDTX
Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations
globenewswire.com
CDTX